In July 2014 Codexis, a biotechnology company based in Redwood City, California, US, granted GlaxoSmithKline (GSK) a licence to use its CodeEvolver platform technology to develop novel enzymes for use in the manufacture of GSK’s human pharmaceutical and healthcare products. As part of the agreement, which is worth US$25m plus milestones and potential royalties, the CodeEvolver protein engineering platform will be installed at GSK’s research and development site at Upper Merion, Pennsylvania.
This is the first time that Codexis has licensed its protein engineering platform technology to any party in the healthcare field, but it is likely to be the first of a series of similar licences as the pharma industry increasingly recognises the advantages of incorporating enzymatic processes into the manufacture of drugs.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.